Trimelamol for Refractory Ovarian Cancer
Author Information
Author(s): I.R. Judson, A.H. Calvert, M.E. Gore, K. Balmanno, L.A. Gumbrell, T. Perren, E. Wiltshaw
Primary Institution: Institute of Cancer Research and Royal Marsden Hospital
Hypothesis
Does Trimelamol show efficacy in treating refractory ovarian cancer?
Conclusion
Trimelamol has limited activity in treating advanced ovarian cancer that is resistant to previous treatments.
Supporting Evidence
- 42 patients were treated with Trimelamol.
- There was one complete response and three partial responses.
- The overall objective response rate was 9.5%.
- Most patients experienced grade 3 nausea and vomiting.
- Haematological toxicity was mild with a median leukocyte nadir of 3.8 x 10^9 l-1.
Takeaway
This study tested a new drug called Trimelamol on women with tough ovarian cancer, but it didn't work very well.
Methodology
Patients with advanced ovarian cancer were treated with Trimelamol at a dose of 800 mg/m2 daily for 3 days every 3 weeks.
Potential Biases
Potential bias in patient selection due to the nature of phase II trials.
Limitations
The response rate was low and the study involved patients with extensive prior therapy.
Participant Demographics
Patients had a median age of 57 and included those with stage III and IV ovarian cancer.
Want to read the original?
Access the complete publication on the publisher's website